Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

NCT06926920 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06926920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 30, 2025
Completion date
June 30, 2028
Enrollment
100 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer